Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...

Blujepa, the brand name for gepotidacin ... According to GSK, 16 million women in the U.S. struggle with UTIs each year, and half of all women experience a UTI in their lifetime, with some 30% of ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

In clinical trials, Blujepa showed efficacy similar or superior to a leading existing UTI treatment, making it a valuable alternative. While Blujepa is generally well tolerated, the most common ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children over the age of 12 with uncomplicated UTIs caused by bacteria including E.

In two studies with over 3,000 women and children who had a mild UTI, Blujepa, a pill taken twice a day for five days, worked as well as or better than nitrofurantoin, a common UTI antibiotic.

Blujepa is approved to treat females 12 and older with uncomplicated urinary tract infections, or UTIs. About half of all women will experience a UTI at some point in their lives, and about 30% ...

“The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific Officer, GSK. “We are proud to have developed ...

In clinical trials, Blujepa showed efficacy similar or superior to a leading existing UTI treatment, making it a valuable alternative. While Blujepa is generally well tolerated, the most common ...